UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prognostic and predictive significance of MSI in stages Ⅱ/Ⅲ colon cancer

World journal of gastroenterology : WJG, 2014-06, Vol.20 (22), p.6809-6814

2014

Volltextzugriff (PDF)

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

PloS one, 2011-01, Vol.6 (1), p.e15980

2011

Volltextzugriff (PDF)

BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome

PloS one, 2013-12, Vol.8 (12), p.e84604-e84604

2013

Volltextzugriff (PDF)

Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

World journal of gastroenterology : WJG, 2010-03, Vol.16 (10), p.1177-1187

2010

Volltextzugriff (PDF)

VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity

Annals of oncology, 2017-06, Vol.28, p.iii151-iii152

2017

Volltextzugriff (PDF)

Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer

Cancer letters, 2010-02, Vol.288 (1), p.99-106

2010

Volltextzugriff (PDF)

Gefitinib in Combination with Gemcitabine and Vinorelbine in Patients with Metastatic Breast Cancer Pre-treated with Taxane and Anthracycline Chemotherapy: A Phase I/II Trial

Anticancer research, 2008-09, Vol.28 (5B), p.3019-3025

2008

Volltextzugriff (PDF)

Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle

JNCI : Journal of the National Cancer Institute, 2011-06, Vol.103 (11), p.841-844

2011

Volltextzugriff (PDF)

Abstract P5-13-01: Comprehensive tumor analysis by NGS in metastatic breast cancer patients

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-01

2022

Volltextzugriff (PDF)

Frequent germline BRCA1/2 mutations in women with ovarian cancer and the need for insurance coverage of genetic testing: A Hellenic Society of Medical Oncology (HeSMO) national program

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13525-e13525

2018

Volltextzugriff (PDF)

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

Cancers, 2021-01, Vol.13 (2), p.198

2021

Volltextzugriff (PDF)

Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3538-3538

2017

Volltextzugriff (PDF)

Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group

ESMO open, 2020-08, Vol.5 (4), p.e000774, Article e000774

2020

Volltextzugriff (PDF)

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer

Cancer chemotherapy and pharmacology, 2012, Vol.69 (1), p.35-42

2012

Volltextzugriff (PDF)

Mechanisms f resistance o anti-EEGFR monoclonal antibody treatment in metastatic colorectal cancer

世界胃肠病学杂志(英文版), 2010, Vol.16 (10), p.1177-1187

2010

Volltextzugriff (PDF)

Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer

Clinical cancer research, 2011, Vol.17 (1), p.165-173

2011

Volltextzugriff (PDF)

Career Development and Oncology Education in Europe: Final results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18202-e18202

2016

Volltextzugriff (PDF)

Pkm2 Expression Could Predict Resistance to Oxaliplatin Combination Chemotherapy in Patients with Stage Ii/Iii or Metastatic Colorectal Cancer

Annals of oncology, 2013-06, Vol.24, p.iv115-iv115

2013

Volltextzugriff (PDF)

Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma

American journal of clinical oncology, 2015-02, Vol.38 (1), p.17-22

2015

Volltextzugriff (PDF)

PKM2 mRNA expression to predict disease recurrence in patients with stage II or III colon cancer treated with oxaliplatin in combination with fluoropyrimidines

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.468-468

2012

Volltextzugriff (PDF)

Continuous Administration of Daily Low-Dose Temozolomide in Pretreated Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study

Oncology, 2009-02, Vol.76 (2), p.112-117

2009

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(39)
Berichte
(1)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(20)
Humans
(19)
Oncology
(19)
Aged
(16)
Female
(15)
Middle Aged
(14)
Adult
(12)
Male
(12)
Tumors
(12)
Chemotherapy
(10)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Treatment Outcome
(8)
Aged, 80 And Over
(7)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(7)
Deoxycytidine - Administration & Dosage
(7)
Deoxycytidine - Analogs & Derivatives
(7)
Mutation
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prognostic and predictive significance of MSI in stages Ⅱ/Ⅲ colon cancer

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome

Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity

Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer

Gefitinib in Combination with Gemcitabine and Vinorelbine in Patients with Metastatic Breast Cancer Pre-treated with Taxane and Anthracycline Chemotherapy: A Phase I/II Trial

Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle

Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group

Abstract P5-13-01: Comprehensive tumor analysis by NGS in metastatic breast cancer patients

Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer

Frequent germline BRCA1/2 mutations in women with ovarian cancer and the need for insurance coverage of genetic testing: A Hellenic Society of Medical Oncology (HeSMO) national program

Screening of colorectal cancer (CRC) patients for lynch syndrome (LS) emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity

Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer

Mechanisms f resistance o anti-EEGFR monoclonal antibody treatment in metastatic colorectal cancer

Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer

Career Development and Oncology Education in Europe: Final results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO)

Pkm2 Expression Could Predict Resistance to Oxaliplatin Combination Chemotherapy in Patients with Stage Ii/Iii or Metastatic Colorectal Cancer

Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma

PKM2 mRNA expression to predict disease recurrence in patients with stage II or III colon cancer treated with oxaliplatin in combination with fluoropyrimidines

Continuous Administration of Daily Low-Dose Temozolomide in Pretreated Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study

Suchergebnisse filtern